Laura Augusta Gonella

Dr. Laura Augusta Gonella

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
LGLaura Augusta Gonella
Laura Augusta Gonella
FMFrancesca Moretti
Francesca Moretti
ACAnnalisa Capuano
Annalisa Capuano
CSCaterina De Sarro
Caterina De Sarro
LFLorenza Ferrara
Lorenza Ferrara
VGVigiVax Working Group
VigiVax Working Group
Underreporting is the main limitation of spontaneous reporting systems. This cohort-event monitoring study aims to examine the potential of short message service (SMS)-based surveillance compared to traditional surveillance systems. Using VigiVax software, parents of vaccinated children aged two years or younger, in the period March 2021–May 2022, received a single SMS inquiry about adverse events following immunization (AEFI). Responses were collected, validated by health operators and integrated with the information on electronic immunization registries. AEFI reports were automatically submitted to the Italian Pharmacovigilance system. Among 254,160 SMS messages sent, corresponding to 451,656 administered doses (AD), 71,643 responses were collected (28.2% response rate), and 21,231 of them (8.3%) reported AEFI. After a seriousness assessment based on clinical criteria, 50 reports (0.24%) were classified as serious. Among these, a causality assessment identified 31 reports at least potentially related to the vaccination (RR: 6.86/100,000 AD). Febrile seizures following MMRV (measles, mumps, rubella, varicella) vaccination accounted for 11 of these 31 cases, with an incidence of 32 per 100,000 AD. No fatal outcomes were reported. Our findings support the highly favorable risk profile of pediatric vaccinations and the possibility to improve spontaneous reporting through the integration of digital technologies.

18 July 2023 in Phytotherapy Research
Verified
Journal Article
Open access
LGLaura Augusta Gonella
Laura Augusta Gonella
VMValentina Maggini
Valentina Maggini
EREmanuel Raschi
Emanuel Raschi
LGLaura Augusta Gonella
Laura Augusta Gonella
NLNicoletta Luxi
Nicoletta Luxi
NLNiccolò Lombardi
Niccolò Lombardi
The safety of Serenoa repens (SR)‐containing products was evaluated conducting a retrospective worldwide analysis of pharmaco‐ and phytovigilance report forms of suspected adverse reactions (SARs) collected up to 31 January 2022. Multivariate logistic regression was performed to estimate the odds ratios (ORs) of serious SAR. A total of 1810 report forms were analysed; 92% of subjects were males, with a median age of 69 years; 44% of cases were defined as serious. Subjects exposed to dietary supplements had a higher risk of developing serious SARs (OR: 1.60 [95% CI: 1.20–2.15]), as subjects exposed to 2–5 (OR: 1. 83 [95% CI: 1.30–2.58]) or more than 5 (OR: 3.45 [95% CI: 2.36–5.06]) suspect/interacting products. The probability of experiencing serious SAR was higher for subjects exposed to concomitant products (OR: 1.55 [95% CI: 1.15–2.08]), to more than four active compounds (OR: 4.38 [95% CI: 3.21–5.99]) and to SR for more than 14 days (OR: 1.89 [95% CI: 1.10–3, 22]), and lower for subjects exposed to higher doses of SR (OR: of 0.34 [95% CI: 0.20–0.58]). This evidence improves awareness on safety of SR containing products, suggesting the need of a further update of periodic reviews by national and international regulatory agencies.

24 August 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FMF. Moretti
F. Moretti
LGLaura Augusta Gonella
Laura Augusta Gonella
SGS. Gironi
S. Gironi
AMA. R. Marra
A. R. Marra
CSC. Santuccio
C. Santuccio
UMUgo Moretti
Ugo Moretti
Reporting and analysis of Adverse Events Following Immunization (AEFIs) are the cornerstones of vaccine safety surveillance prompting causality assessment and signal detection. This paper describes the impact of the Italian Pharmacovigilance System of vaccines over a 10-year period (2008–2017). The reporting rate (RR) per all distributed dose was calculated. Serious AEFIs and causality assessments for fatal cases were described. The main results from signal detection were reported. During the study period, 46,430 AEFIs were reported with an overall RR of 17.2 per 100,000 distributed doses. Italy showed the highest number of reports among European countries. Only 4.4% of the reports came from citizens. Of the total, 12.7% were classified as serious with a RR over the study period of 2.20 per 100,000 distributed doses. They were mainly related to hyperpyrexia and usually had a positive outcome. Fatal outcomes were reported in 0.3% of the cases and were primarily associated with the influenza vaccine in elderly patients. None of these outcomes had a consistent causal association with the vaccination. Febrile convulsions by the measles, mumps, rubella and varicella vaccines and intussusception by the rotavirus vaccine were among the highlighted signals. The reporting rate and the analysis of serious events from 10 years support the good risk/benefit profiles of vaccines.

21 June 2024 in Vaccine: X
Verified
Journal Article
Open access
DVDiana Dalla Valle
Diana Dalla Valle
RBRoberto Benoni
Roberto Benoni
NSNicola Soriolo
Nicola Soriolo
CBChiara Battistella
Chiara Battistella
FMFrancesca Moretti
Francesca Moretti
GZGiovanna Zanoni
Giovanna Zanoni
In Veneto Region, HPV vaccine has been actively offered to 12 year-old females since 2008, and to 12 year-old males since 2015. The study aims to analyze the safety profile of HPV4v and HPV9v vaccines and perform a case-by-case review of conditions of interest.

6 April 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
FMFrancesca Menniti-Ippolito
Francesca Menniti-Ippolito
EAEugenio Aiello
Eugenio Aiello
EAElena Arzenton
Elena Arzenton
AAAlessandro Assisi
Alessandro Assisi
UBUrška Blaznik
Urška Blaznik
GRGwenn Vo Van Regnault
Gwenn Vo Van Regnault

29 March 2024 in Preventive Medicine Reports
Verified
Journal Article
Open access
NSNicola Soriolo
Nicola Soriolo
RBRoberto Benoni
Roberto Benoni
DVDiana Dalla Valle
Diana Dalla Valle
FZFrancesco Zunino
Francesco Zunino
AOAdele Olivieri
Adele Olivieri
LGLaura Augusta Gonella
Laura Augusta Gonella
The vaccines for measles, mumps, rubella and varicella (MMR and V) have been mandatory in Italy since 2017. Two different vaccination strategies are suggested for the first dose: trivalent MMR and a separate V vaccine or the tetravalent MMRV vaccine. Our aim is to compare the safety profile of MMRV and MMR-V vaccines through the passive adverse event reporting system in the Veneto region and to perform a case-by-case review of a few conditions of interest (febrile and afebrile seizures, ataxia, encephalitis, Guillain-Barré Syndrome, thrombocytopenia, neutropenia and Henoch-Schönlein Purpura). Age and sex differences were also explored. We identified all reports following MMRV or MMR-V vaccination in the Veneto Region and received into the National Pharmacovigilance Network between 2007 and April 30, 2022. 9,510 reports were retrieved, of which 5,662 (59.5 %) were related to MMRV and 3,848 (40.5 %) to MMR-V. No safety signals were detected supporting the evidence that MMRV and MMR-V vaccinations have a good safety profile. The reporting rate (RR) for serious events between 2007 and 2022 resulted in 13.67 per 10,000 administered doses for MMRV and 10.90 for MMR-V. Passive surveillance data show a significantly higher rate of serious events for males 0-2 years old, both overall and stratified per vaccination strategy. Further studies are needed to confirm this observation. The analyses suggest that retrieved differences do not have a significant impact on the overall safety of both formulations.